Therefore, the combination of cytofluorimetric and transcriptomic experiments provided solid evidence for a reduction in the intermediate (CD14++CD16+) and non-classical (CD14+CD16++) peripheral blood monocyte subsets in IVIg-treated CVID patients, a result that fits with the transcriptional data and is in agreement with previous reports [54]. This evidence concerns the gene CD14 and common variable immunodeficiency.